



Fee-for Service Prior Authorization Criteria
Zelepar (selegiline) rapidly disintegrating tablets 1.25mg

Description: An irreversible MOA-B inhibitor intended for oral mucosal absorption.
Dose: 1.25mg QD x 6 weeks, then 2.5mg QD
AWP \$4.67/tab

Zelepar Criteria

- Patient has Parkinson's disease

AND

- Patient is on levodopa/carbidopa and is experiencing significant "off" periods or a deterioration in the quality of their response to therapy.

AND

- Patient has tried a 5mg dose of oral selegiline tablets or capsules but has had therapeutic failure due to adverse events.